A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

March 31, 2021

Study Completion Date

May 31, 2021

Conditions

Solid Tumor

Interventions

DRUG

Oraxol

Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.

Trial Locations (3)

Roswell Park Cancer Institute, Buffalo

Cancer Therapy &Research Center @ UTHSCSA, San Antonio

Dana Farber Cancer Institute, Boston